Search Results
You are looking at 1 - 2 of 2 items for
- Author: Woong-Yang Park x
- Refine by access: All content x
Samsung Genome Institute, Internal Medicine, Surgery, Biomedical Sciences, Department of Internal Medicine, Department of Molecular Cell Biology, Samsung Medical Center, 50 Irwondong, Gangnamgu, Seoul 135-710, Korea Departments of
Search for other papers by Gahee Park in
Google Scholar
PubMed
Search for other papers by Tae Hyuk Kim in
Google Scholar
PubMed
Search for other papers by Hae-Ock Lee in
Google Scholar
PubMed
Samsung Genome Institute, Internal Medicine, Surgery, Biomedical Sciences, Department of Internal Medicine, Department of Molecular Cell Biology, Samsung Medical Center, 50 Irwondong, Gangnamgu, Seoul 135-710, Korea Departments of
Search for other papers by Jung Ah Lim in
Google Scholar
PubMed
Search for other papers by Jae-Kyung Won in
Google Scholar
PubMed
Search for other papers by Hye Sook Min in
Google Scholar
PubMed
Search for other papers by Kyu Eun Lee in
Google Scholar
PubMed
Search for other papers by Do Joon Park in
Google Scholar
PubMed
Search for other papers by Young Joo Park in
Google Scholar
PubMed
Samsung Genome Institute, Internal Medicine, Surgery, Biomedical Sciences, Department of Internal Medicine, Department of Molecular Cell Biology, Samsung Medical Center, 50 Irwondong, Gangnamgu, Seoul 135-710, Korea Departments of
Samsung Genome Institute, Internal Medicine, Surgery, Biomedical Sciences, Department of Internal Medicine, Department of Molecular Cell Biology, Samsung Medical Center, 50 Irwondong, Gangnamgu, Seoul 135-710, Korea Departments of
Search for other papers by Woong-Yang Park in
Google Scholar
PubMed
The anaplastic lymphoma kinase (ALK) gene is frequently rearranged in various types of cancer and is highly responsive to targeted therapeutics. We developed a system to detect rearrangement of ALK in a large group of Korean thyroid cancer patients. We screened 474 malignant or benign thyroid tumor cases to identify ALK fusions. Expression and translocation of the ALK gene were analyzed by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and digital multiplexed gene expression (DMGE) analysis in formalin-fixed paraffin-embedded tissues. Four cases of rearrangement of ALK were detected by IHC, and these cases were validated with FISH on 189 samples. On the other hand, DMGE analysis using Nanostring detected three out of four IHC-positive cases. Two rearrangements of ALK were striatin (STRN)–ALK fusions, which were identified by 5′ RACE analysis. Rearrangements of ALK were found exclusively in v-raf murine sarcoma viral oncogene homolog B (BRAF) WT papillary carcinomas. Given the wide availability and accuracy of IHC for detecting ectopic expression of ALK in the thyroid, we suggest that IHC-based screening can be a practical method for identifying patients with ALK rearrangements in differentiated thyroid cancer.
Search for other papers by Tae Hyuk Kim in
Google Scholar
PubMed
Search for other papers by Young-Eun Kim in
Google Scholar
PubMed
Search for other papers by Soomin Ahn in
Google Scholar
PubMed
Search for other papers by Ji-Youn Kim in
Google Scholar
PubMed
Search for other papers by Chang-Seok Ki in
Google Scholar
PubMed
Search for other papers by Young Lyun Oh in
Google Scholar
PubMed
Search for other papers by Kyunga Kim in
Google Scholar
PubMed
Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Korea
Search for other papers by Jae Won Yun in
Google Scholar
PubMed
Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Korea
Search for other papers by Woong-Yang Park in
Google Scholar
PubMed
Search for other papers by Jun-Ho Choe in
Google Scholar
PubMed
Search for other papers by Jung-Han Kim in
Google Scholar
PubMed
Search for other papers by Jee Soo Kim in
Google Scholar
PubMed
Search for other papers by Sun Wook Kim in
Google Scholar
PubMed
Search for other papers by Jae Hoon Chung in
Google Scholar
PubMed
TERT promoter mutations are emerging prognostic biomarkers in multiple cancers and are found in highly aggressive thyroid cancer. Our aim is to investigate the prognostic value of these mutations for the outcome of thyroid cancer-related mortality in a large cohort of thyroid cancer patients. This was a retrospective study of 409 patients (393 with differentiated thyroid cancer) with a median age of 44 years (range 16–81 years) and median follow-up of 13 years (interquartile range 11–16 years). Analyses of associations between mutational status and various clinicopathological variables were performed. TERT promoter mutations were identified in 32 (9.8%) papillary, 11 (16.7%) follicular and seven (43.8%) poorly differentiated/anaplastic thyroid cancer patients. The presence of TERT promoter mutations was associated with factors such as increased age (P < 0.001), extrathyroidal invasion (P = 0.01), increased stage at diagnosis (P < 0.001) and dedifferentiated histological type (P = 0.001). A TERT promoter mutation was independently associated with poorer overall survival in patients with differentiated thyroid cancer (10-year survival rate, 66.2% vs 98.3% for wild type; adjusted HR, 7.18; 95% CI: 2.77–18.59) and in patients with papillary cancer (74.2% vs 99.3%; 14.20; 3.03–66.68). Concomitant TERT and BRAF mutations worsened the survival rate of patients with papillary cancer (82.6% vs 99.4% for exclusively BRAF mutation alone; 5.62; 1.85–17.09). In conclusion, the presence of TERT promoter mutations is independently associated with increased mortality in patients with differentiated thyroid cancer. The results suggest that inclusion of TERT promoter mutation analysis with conventional clinicopathological evaluation can lead to better prognostication and management for individual patients.